Nike sales recovery pushed back as Bank of America cuts earnings forecast

Bank of America lowered its earnings forecast for Nike (NKE), pushing back its expected growth recovery to Q3 2028 due to weakness in the Jordan business. The firm cut its 2028 EPS estimate by 11% to $1.31 but maintained a $24 price target. Nike's sales are projected to decline 9% in 2028, 1% in 2029, and then grow 4% annually through 2031, leaving revenue flat compared to 2026 levels. The broker also expressed concerns about Nike's dividend sustainability.

Original reporting
Published Nov 10, 2026, 7:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nike sales recovery pushed back as Bank of America cuts earnings forecast — source image
Decision brief

The 30-second read

$NKEBearishMed
01

Why it matters

The forecast cut signals weaker demand for Nike's Jordan line and may prompt short‑term price declines.

02

Market read

Analyst downgrade introduces new downside risk for Nike and could affect related consumer discretionary stocks.

03

What to watch

Potential upside from upcoming investor day and any surprise product launches could mitigate the forecast cut.

Relevance 7/10Novelty 7/10Timing: today

Background

Bank of America revised its earnings model for Nike, lowering FY2028 EPS and extending the timeline for a sales recovery.

Company-level read

Ticker impact

$NKEBearishMedium confidence
Context

Bank of America cut Nike's FY2028 earnings per share estimate by 11% and pushed the inflection point to Q3 2028, indicating weaker near‑term performance.

Expected impact

downward pressure as the market prices in the earnings forecast cut

Evidence & confidence

The 11% EPS reduction and delayed inflection point are new, material revisions that typically trigger a sell‑off in the short term.

Market effects

The downgrade may weigh on the broader apparel and consumer discretionary sector as peers face similar demand challenges.

U.S. equity markets could see modest weakness in consumer stocks.

Limited to markets with exposure to Nike; no immediate global macro effect.

Counterpoint

If Nike's cost‑saving PACE programme delivers faster than expected, the stock could rebound despite the downgrade.

Key entities

  • Nike Inc.

    Global sportswear and apparel manufacturer.

  • Bank of America

    Equity research analyst providing the earnings forecast revision.

Related articles

$TDUPMed

Analysts Have Conflicting Sentiments on These Consumer Cyclical Companies: thredUP (TDUP), Texas Roadhouse (TXRH) and Nike (NKE)

Analysts from Wells Fargo and others updated ratings on thredUP (TDUP), Texas Roadhouse (TXRH), and Nike (NKE). thredUP received a Buy rating with a $3.00 target, Texas Roadhouse a Buy with a $220.00 target, and Nike a Hold with a $34.00 target. Consensus ratings and targets vary for each company, with thredUP showing the highest upside potential.

$NKEMed

Nike Stock Climbs 19% in a Month as Morgan Stanley Cuts Target to $25 and Calls Reset Unfinished — BigGo Finance

Nike (NKE) shares rose 19% in a month, but Morgan Stanley cut its price target to $25, arguing the company's sales reset is unfinished. Revenue fell 4% to $11.21B in Q1, with sportswear and Jordan categories declining. Management expects high-single-digit revenue decline for the fiscal year. Morgan Stanley sees potential downside at the upcoming investor day, with sales expected to settle near $40B, 22% below the 2024 peak.

$NKEHigh

Truist downgrades Nike to Sell, says rally ignores ongoing risks

Truist downgraded Nike (NKE) to Sell, maintaining a $29 price target. The firm argues the stock's 19% rally doesn't reflect business improvements, citing valuation at 27x earnings and risks in Sportswear and Jordan businesses. Analysts note challenges in running, China, and recent underperforming product launches. Fiscal 2028 EPS estimate was cut to $1.30, below consensus of $1.50.